Cargando…

Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment

OBJECTIVE: To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients. METHODS: This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confir...

Descripción completa

Detalles Bibliográficos
Autores principales: Okumura, Lucas M., Antunes, Valquíria D., Aguiar, Karina S., Farias, Tatiane, Andrzejevski, Vânia M., Funke, Vaneuza M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centro de Investigaciones y Publicaciones Farmaceuticas 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482844/
https://www.ncbi.nlm.nih.gov/pubmed/26131044
_version_ 1782378507575230464
author Okumura, Lucas M.
Antunes, Valquíria D.
Aguiar, Karina S.
Farias, Tatiane
Andrzejevski, Vânia M.
Funke, Vaneuza M.
author_facet Okumura, Lucas M.
Antunes, Valquíria D.
Aguiar, Karina S.
Farias, Tatiane
Andrzejevski, Vânia M.
Funke, Vaneuza M.
author_sort Okumura, Lucas M.
collection PubMed
description OBJECTIVE: To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients. METHODS: This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confirmed during pharmacists’ consultation (patient-reported adherence). Baseline characteristics between groups were compared between cases and controls groups. Risk factors identified in bivariate analysis (p<0.2) were included in multivariate model. A qualitative investigation assessed whether such predictors of non-adherence had causal relationship. RESULTS: Of 151 patients with CML consulted by pharmacists, 21% had adherence problems. Despite patients with secondary school (p=0.03), most of investigated social risk factors did not differ between groups. However, by using a qualitative approach, patients’ level of education could not explain low adherence rates behavior. CONCLUSIONS: Social determinants of health, herein investigated, were unlikely to predict adherence to treatment. Regression techniques may lead to untrue statements, so future researches should consider investigating the causes, not only the statistical estimates.
format Online
Article
Text
id pubmed-4482844
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Centro de Investigaciones y Publicaciones Farmaceuticas
record_format MEDLINE/PubMed
spelling pubmed-44828442015-06-30 Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment Okumura, Lucas M. Antunes, Valquíria D. Aguiar, Karina S. Farias, Tatiane Andrzejevski, Vânia M. Funke, Vaneuza M. Pharm Pract (Granada) Original Research OBJECTIVE: To assess the role of social risk factors on adherence to tyrosine kinase inhibitors (TKI) therapy in chronic myeloid leukemia (CML) patients. METHODS: This is a retrospective study and eligible patients were adults with CML on TKI treatment. Cases of no adherence to treatment were confirmed during pharmacists’ consultation (patient-reported adherence). Baseline characteristics between groups were compared between cases and controls groups. Risk factors identified in bivariate analysis (p<0.2) were included in multivariate model. A qualitative investigation assessed whether such predictors of non-adherence had causal relationship. RESULTS: Of 151 patients with CML consulted by pharmacists, 21% had adherence problems. Despite patients with secondary school (p=0.03), most of investigated social risk factors did not differ between groups. However, by using a qualitative approach, patients’ level of education could not explain low adherence rates behavior. CONCLUSIONS: Social determinants of health, herein investigated, were unlikely to predict adherence to treatment. Regression techniques may lead to untrue statements, so future researches should consider investigating the causes, not only the statistical estimates. Centro de Investigaciones y Publicaciones Farmaceuticas 2015 2015-06-15 /pmc/articles/PMC4482844/ /pubmed/26131044 Text en Copyright: © Pharmacy Practice http://creativecommons.org/licenses/by-nc-nd/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Okumura, Lucas M.
Antunes, Valquíria D.
Aguiar, Karina S.
Farias, Tatiane
Andrzejevski, Vânia M.
Funke, Vaneuza M.
Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
title Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
title_full Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
title_fullStr Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
title_full_unstemmed Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
title_short Tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
title_sort tyrosine kinase inhibitors in patients with chronic myelogeneous leukemia: defining the role of social risk factors and non-adherence to treatment
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4482844/
https://www.ncbi.nlm.nih.gov/pubmed/26131044
work_keys_str_mv AT okumuralucasm tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment
AT antunesvalquiriad tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment
AT aguiarkarinas tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment
AT fariastatiane tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment
AT andrzejevskivaniam tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment
AT funkevaneuzam tyrosinekinaseinhibitorsinpatientswithchronicmyelogeneousleukemiadefiningtheroleofsocialriskfactorsandnonadherencetotreatment